Tagged with BI

QuantiLAB After recently signing a service level agreement with Mérieux NutriSciences in May 2015, Bertrand Baudot, Managing Director of QuantiLAB explains the company’s plans for the future. He also discusses the challenges and, more importantly, highlights the various opportunities in the Healthcare and Life Sciences sector on Mauritius. In its first…

pharma Agustín Rullán, Dean of the College of Engineering at UPR Mayagüez, discusses the institution’s latest developments in engineering courses and their applicability in a practical industrial setting for students to jumpstart their professional careers. As a leading engineering college with 4,300 undergraduates and 400 graduates, the College plays a very…

Pharma The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market with tremendous potential at the world level; how the factory has a particularly strong international exposure, exporting 75 percent of…

Pharma The CEO of BioTech Africa, Jason Lurie, evaluates the domestic and global landscape for diagnostic recombinant proteins, and highlights other developmental streams that have helped diversify the company’s portfolio. He also illustrates the underlying aspirations in targeting this market niche, while depicting the distinct set of hurdles faced from the…

Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…

France The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to maintain their competitiveness. He also discusses his company’s recent merger with Biostatem and their mission to internationalize. While France remains…

Netherlands The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of cancer, discusses the company’s most recent milestones as well as how it is fostering a collaborative model based on partnerships.…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…

pharma The CEO of BioConnection, the leading contract services and manufacturing organization for the development and production of injectable (bio)pharmaceutical products, explains how —thanks to flexibility and quality-driven mentality —the company helps small and medium biotech companies and universities make their products reality. This year BioConnection celebrates its tenth anniversary and…

pharma The Netherlands provides a flourishing environment for biotech to grow. The vice president for European operations at Kite Pharma discusses how biotech start-ups can find their path to success and how Kite Pharma is looking at new innovative therapies for cancer treatment. Before joining T-Cell Factory, later acquired by Kite…

pharma Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success. In 2014/2015, three Dutch biotechs (UniQure, ProQR, Galapagos) went public on Nasdaq, and…

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…